All News #Library
Sciences
Aptose Begins Dosing AML Patients With Tuspetinib Triplet In Trial
09 Jan 2025 //
GLOBENEWSWIRE
Aptose Initiates Ph 1/2 Study In Newly Diagnosed AML Patients
20 Nov 2024 //
GLOBENEWSWIRE

Market Place
Sourcing Support